Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Marine Gilabert,1,2 Jean-Luc Raoul3 1Department of Medical Oncology, Paoli-Calmettes Institute, 13232 Marseille Cedex 9, France; 2Centre de Recherche en Cancérologie de Marseille, Stress Cell Unit, Institut National de la Sante et de la Recherche Medicale 1068, Aix-Marseille University, C...

Full description

Bibliographic Details
Main Authors:	Gilabert M, Raoul JL
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	hepatocellular carcinoma antiangiogenics ramucirumab
Online Access:	https://www.dovepress.com/potential-of-ramucirumab-in-treating-hepatocellular-carcinoma-patients-peer-reviewed-article-JHC

Similar Items

Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
by: Chia-Jui Yen, et al.
Published: (2020-05-01)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
by: De Luca E, et al.
Published: (2020-05-01)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
by: James J. Harding, et al.
Published: (2021-05-01)

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
by: Yoshiyuki Wada, et al.
Published: (2020-04-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
by: Masatoshi Kudo, et al.
Published: (2021-07-01)

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
by: Xiao B, et al.
Published: (2018-08-01)

Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy
by: Keiko Akahane, et al.
Published: (2020-05-01)

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
by: Ming-Huang Chen, et al.
Published: (2021-07-01)

Second-line treatment options in hepatocellular carcinoma
by: Donatella Marino, et al.
Published: (2019-04-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-02-01)

Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment
by: Takeshi Hatanaka, et al.
Published: (2020-10-01)

Treatment options after sorafenib failure in patients with hepatocellular carcinoma
by: Imane El Dika, et al.
Published: (2017-12-01)

Second-line treatment of hepatocellular carcinoma: from theory to practical issues
by: V. V. Breder, et al.
Published: (2019-12-01)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
by: Maria Angeles Gil-Delgado, et al.
Published: (2018-08-01)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
by: Raybould AL, et al.
Published: (2020-09-01)

Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma
by: Joon Seong Ahn, et al.
Published: (2013-06-01)

Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?
by: Chao-Wei Lee, et al.
Published: (2019-10-01)

Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
by: Young-Joo Jin, et al.
Published: (2020-12-01)

Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation
by: Gauri Mishra, et al.
Published: (2020-05-01)

Ramucirumab: Boon or bane
by: Priya Tiwari
Published: (2016-09-01)

Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies
by: Aejaz Nasir, et al.
Published: (2017-05-01)

Racial disparities in alpha‐fetoprotein testing and alpha‐fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients
by: Guoyi Wu, et al.
Published: (2019-11-01)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
by: Lee SH, et al.
Published: (2015-04-01)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
by: Cooper MR, et al.
Published: (2016-04-01)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
by: Shinnosuke Takemoto, et al.
Published: (2020-02-01)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
by: Ayako Shiono, et al.
Published: (2019-04-01)

Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma
by: Jian Hu, et al.
Published: (2018-12-01)

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
by: Justin B. Wenger, et al.
Published: (2011-09-01)

The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia
by: Chyntia Olivia Maurine Jasirwan, et al.
Published: (2020-07-01)

Late solitary pelvic metastasis of hepatocellular carcinoma mimicking alpha-fetoprotein-producing gynaecologic tumour
by: Ji He Kim, et al.
Published: (2018-01-01)

The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population
by: Young Sun Ko, et al.
Published: (2017-04-01)

Preclinical assessment of intravitreal ramucirumab: in vitro and in vivo safety profile
by: Jarbas Emílio de Moraes Neto, et al.
Published: (2020-09-01)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
by: Atsuto Mouri, et al.
Published: (2019-04-01)

Comparative Evaluation of Alpha-Fetoprotein Serum in Hepatocellular Carcinoma Patients with Non-Viral Etiology
by: Gita Aprilicia, et al.
Published: (2021-03-01)

Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas
by: Sejong Chun, et al.
Published: (2015-11-01)

Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes
by: Jianping Sun, et al.
Published: (2019-10-01)

Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis
by: Sun TT, et al.
Published: (2018-12-01)

Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma
by: JIA Jia
Published: (2013-08-01)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
by: Sadayuki Kawai, et al.
Published: (2020-04-01)